Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HELP NASDAQ:IKT NASDAQ:NERV NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHELPCybin$5.28-1.1%$5.47$4.29▼$9.83$272.61M0.8976,270 shs195,164 shsIKTInhibikase Therapeutics$2.08+4.3%$1.84$1.33▼$2.27$275.35M0.961.56 million shs131,425 shsNERVMinerva Neurosciences$5.99-2.3%$6.51$1.30▼$12.46$279.03M-0.08201,280 shs10,348 shsTCRXTScan Therapeutics$1.28+5.4%$1.11$0.88▼$2.57$72.55M1.06736,211 shs500,738 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHELPCybin-3.61%+0.56%+1.71%-10.70%+533,999,900.00%IKTInhibikase Therapeutics-1.00%+5.29%+13.07%+17.06%+198,999,900.00%NERVMinerva Neurosciences-1.61%-5.26%+18.34%+27.71%+279.57%TCRXTScan Therapeutics-3.20%+4.31%+13.08%+17.48%-13.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHELPCybin$5.28-1.1%$5.47$4.29▼$9.83$272.61M0.8976,270 shs195,164 shsIKTInhibikase Therapeutics$2.08+4.3%$1.84$1.33▼$2.27$275.35M0.961.56 million shs131,425 shsNERVMinerva Neurosciences$5.99-2.3%$6.51$1.30▼$12.46$279.03M-0.08201,280 shs10,348 shsTCRXTScan Therapeutics$1.28+5.4%$1.11$0.88▼$2.57$72.55M1.06736,211 shs500,738 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHELPCybin-3.61%+0.56%+1.71%-10.70%+533,999,900.00%IKTInhibikase Therapeutics-1.00%+5.29%+13.07%+17.06%+198,999,900.00%NERVMinerva Neurosciences-1.61%-5.26%+18.34%+27.71%+279.57%TCRXTScan Therapeutics-3.20%+4.31%+13.08%+17.48%-13.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHELPCybin 3.17Buy$58.751,000.19% UpsideIKTInhibikase Therapeutics 3.13Buy$5.50176.38% UpsideNERVMinerva Neurosciences 2.00Hold$10.5071.29% UpsideTCRXTScan Therapeutics 2.33Hold$6.00395.87% UpsideCurrent Analyst Ratings BreakdownLatest TCRX, HELP, NERV, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026IKTInhibikase Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026NERVMinerva Neurosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$14.004/13/2026HELPCybin TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/27/2026NERVMinerva Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/12/2026NERVMinerva Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$4.00 ➝ $7.003/5/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.003/4/2026IKTInhibikase Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/4/2026IKTInhibikase Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.003/2/2026HELPCybin HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $95.002/23/2026IKTInhibikase Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHELPCybinN/AN/AN/AN/A$7.89 per shareN/AIKTInhibikase Therapeutics$260K1,010.77N/AN/A$2.30 per share0.87NERVMinerva NeurosciencesN/AN/AN/AN/A($5.45) per shareN/ATCRXTScan Therapeutics$10.32M6.67N/AN/A$2.16 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHELPCybin-$81.31M-$4.23N/AN/AN/AN/A-59.98%-50.80%N/AIKTInhibikase Therapeutics-$48.26M-$0.48N/AN/AN/AN/A-46.90%-43.48%N/ANERVMinerva Neurosciences-$293.42M-$29.16N/AN/AN/AN/AN/A-32.63%5/12/2026 (Estimated)TCRXTScan Therapeutics-$129.77M-$1.00N/AN/AN/A-1,360.61%-84.02%-47.23%N/ALatest TCRX, HELP, NERV, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million5/5/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A3/26/2026Q4 2025IKTInhibikase Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/4/2026Q4 2025TCRXTScan Therapeutics-$0.27-$0.18+$0.09-$0.18$2.44 million$2.57 million2/13/2026Q3 2026HELPCybin-$0.53-$0.72-$0.19-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHELPCybinN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHELPCybinN/A13.7813.78IKTInhibikase TherapeuticsN/A21.7021.70NERVMinerva NeurosciencesN/A17.6536.29TCRXTScan Therapeutics0.268.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHELPCybin17.94%IKTInhibikase Therapeutics3.81%NERVMinerva Neurosciences34.56%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipHELPCybin15.00%IKTInhibikase Therapeutics7.30%NERVMinerva Neurosciences10.40%TCRXTScan Therapeutics6.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHELPCybin5051.63 million43.89 millionN/AIKTInhibikase Therapeutics6132.06 million122.42 millionN/ANERVMinerva Neurosciences946.59 million39.28 millionNot OptionableTCRXTScan Therapeutics10056.90 million53.35 millionNot OptionableTCRX, HELP, NERV, and IKT HeadlinesRecent News About These CompaniesQ2 EPS Estimates for TScan Therapeutics Cut by HC Wainwright3 hours ago | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits ExpectationsMay 6 at 3:27 PM | marketbeat.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6 at 9:25 AM | zacks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6 at 7:00 AM | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Hold" by AnalystsMay 5 at 2:40 AM | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from BrokeragesMay 5 at 2:39 AM | marketbeat.comTScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%April 18, 2026 | aaii.comATScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by AnalystsApril 10, 2026 | marketbeat.comTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceMarch 25, 2026 | insidermonkey.comTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03February 26, 2026 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.51%December 25, 2025 | aaii.comATScan Therapeutics (NASDAQ:TCRX) Major Shareholder Acquires $67,950.00 in StockDecember 24, 2025 | insidertrades.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 13.80%December 9, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026$39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent InflationBy Chris Markoch | April 19, 2026TCRX, HELP, NERV, and IKT Company DescriptionsCybin NASDAQ:HELP$5.28 -0.06 (-1.12%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Inhibikase Therapeutics NASDAQ:IKT$2.08 +0.09 (+4.27%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Minerva Neurosciences NASDAQ:NERV$5.99 -0.14 (-2.28%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.TScan Therapeutics NASDAQ:TCRX$1.27 +0.07 (+5.37%) As of 11:13 AM Eastern This is a fair market value price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
